ArticleCureus2025
Association of Dermatological Manifestations in Patients With Type 2 Diabetes Mellitus With Respect to Duration of Diabetes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regenerative Therapies for Cosmetic Dermatology for Patients with Diabetes Mellitus: Skin Aging, Aesthetic Concerns, and Evidence-Based Best Practices.International journal of molecular sciences · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Diabetes mellitus is a disease that can affect various organs, and so all the symptoms should be investigated. Nonetheless, skin symptoms have received less attention than others. The duration of diabetes plays a critical role in the development and progression of systemic and dermatological complications. Existing evidence suggests that many cutaneous complications, such as diabetic dermopathy, xerosis, and infections, tend to increase in frequency and severity with longer disease duration. Therefore, this study assessed and compared the demographic, clinical, lifestyle, and dermatological features of patients with type 2 diabetes mellitus (T2DM) based on the duration of the disease. Methodology This cross-sectional study was performed at multiple secondary care hospitals and primary care centers. The time period of the study was from December 1, 2024, to May 30, 2025. This study included 290 patients with confirmed T2DM, categorized into three groups based on diabetes duration: Group A (less than one year), Group B (one to five years), and Group C (more than five years). Data were collected through clinical examination and structured questionnaires covering demographic details, lifestyle factors, treatment modalities, physiological parameters, and dermatological findings. Statistical analysis was applied using the chi-square test and a Kruskal-Wallis test, with p < 0.05 reflecting statistically significant. Results The comparison of three groups showed significant differences in gender, socioeconomic status, dyslipidemia, smoking history, and diabetes treatment. Group A had more individuals from a high socioeconomic background, while Group C had the most from the middle class. Dermatological conditions such as acanthosis nigricans (p < 0.001), callosities (p = 0.020), and bullae (p = 0.027) were significantly associated with longer diabetes duration. Conclusion This study concluded that the duration of T2DM patients with a longer diabetes duration was linked to lower BMI, better glycemic control, and more lifestyle-based treatments, while shorter duration was associated with higher age, BMI, dyslipidemia, and smoking. Dermatological manifestations such as acanthosis nigricans, callosities, and bullae indicated a significant association with diabetes duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.